Physician Views Preview: Pulmonologists assess new tezepelumab data

Having previously confirmed positive top-line data for its severe asthma therapy tezepelumab in November, development partners Amgen and AstraZeneca will present detailed results at this weekend's virtual American Academy of Asthma Allergy & Immunology (AAAAI) annual meeting.

On Friday, an abstract and press release were issued confirming tezepelumab's overall efficacy and in patients with lower baseline eosinophil counts, which has been touted as an opportunity for Amgen and AstraZeneca to differentiate the product versus other biologic asthma therapies.

We are running a short survey to US and European pulmonologists and respiratory physicians to gauge their reaction to these data and how the launch of tezepelumab could influence prescribing behaviour for severe asthma.

Results will be published in the week beginning February 28, specifically we are asking…

Q. New data being presented this weekend at the virtual AAAAI annual meeting show that tezepelumab, a potential first-in-class medicine for severe, uncontrolled asthma, when added to standard of care (SoC), achieved a 56% reduction in annualised asthma exacerbation rate (AAER) over 52 weeks in the overall patient population, compared to placebo. It reduced the rate of exacerbations associated with hospitalisation or emergency room visit over 52 weeks by 79%.

Tezepelumab is the only biologic medicine to consistently and significantly reduce AAER in a broad population of severe asthma patients irrespective of baseline eosinophil count across Phase II and Phase III trials. In a pre-planned subgroup analysis, tezepelumab achieved a significant and clinically meaningful 41% reduction in AAER in patients with baseline eosinophil counts <300 cells per microlitre. Clinically meaningful reductions in AAER were also observed in two additional subgroups: 39% in patients with baseline eosinophil counts < 150 cells per microlitre and 70% in patients with 300 cells per microlitre.

Clinically meaningful reductions in AAER compared to placebo were also observed in tezepelumab-treated patients irrespective of allergy status and fractional exhaled nitric oxide (FeNO) level.

Assuming tezepelumab is approved by regulators, would you consider switching any of the severe asthma patients you currently treat with a biologic therapy to treatment with tezepelumab, and if so approximately what percentage of patients would you switch?

___%

____________

Q. Assuming tezepelumab is approved, approximately what percentage of severe asthma patients requiring treatment with a biologic therapy for the first time would you considering treating with tezepelumab (instead of an alternative biologic)?

___% 

____________

Q. Tezepelumab achieved a significant and clinically meaningful 41% reduction in AAER in patients with baseline eosinophil counts <300 cells per microlitre. Clinically meaningful reductions in AAER were also observed in two additional subgroups: 39% in patients with baseline eosinophil counts <150 cells per microlitre and 70% in patients with 300 cells per microlitre.

Clinically meaningful reductions in AAER compared to placebo were also observed in tezepelumab-treated patients irrespective of allergy status and fractional exhaled nitric oxide (FeNO) level.

Do you anticipate that these data showing reductions in AAER across subgroups will expand the overall proportion of severe asthma patients who are likely to benefit from treatment with tezepelumab versus other biologic therapies?

No

Yes – up to 10% more patients

Yes – up to 20% more patients

Yes – up to 30% more patients

Yes – up to 40% more patients

Yes – up to 50% more patients

Yes – over 50% more patients

____________

Q. If you anticipate prescribing tezepelumab in the future based on these data, can you please estimate how your use would likely break down by the following patient groups?

Baseline eosinophil counts <150 cells per microlitre ___%

Baseline eosinophil counts between 150 and 300 cells per microlitre ___%

Baseline eosinophil counts ≥300 cells per microlitre ___%

____________

Results and related analysis will shortly be published for FirstWord Pharma PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here

As always, FirstWord would very much like to receive your feedback and suggestions. Note: FirstWord Polls are powered by Medefield MedePolls, a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialties and over 100 markets. To conduct this poll with a different audience, or an entirely different poll, contact us at info@firstwordpharma.com.

To read more Physician Views Poll Results articles, click here.